{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:10:54Z","timestamp":1782101454881,"version":"3.54.5"},"reference-count":21,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:p>Inflammatory myofibroblastic tumor (IMT) is a rare, mesenchymal tumor that has an increased incidence in childhood. Tumors are usually isolated to the chest, abdomen, and retroperitoneum, but metastatic presentations can be seen. Presenting symptoms are nonspecific and include fever, weight loss, pain, shortness of breath, and cough. Approximately 85% of IMTs harbor actionable kinase fusions. The diagnosis can be delayed because of overlapping features with inflammatory disorders, such as elevated inflammatory markers, increased immunoglobin G levels, fever, weight loss, and morphologic similarity with nonmalignant conditions. We present a girl aged 11 years with a TFG-ROS1 fusion\u2013positive tumor of the lung that was initially diagnosed as an immunoglobin G4\u2013related inflammatory pseudotumor. She underwent complete left-sided pneumonectomy and later recurred with widely metastatic disease. We then report the case of a boy aged 9 years with widely metastatic TFG-ROS1 fusion\u2013positive IMT with rapid molecular diagnosis. In both children, there was an excellent response to oral targeted therapy. These cases reveal that rapid molecular testing of inflammatory tumors is not only important for diagnosis but also reveals therapeutic opportunities. Targeted inhibitors produce significant radiologic responses, enabling potentially curative treatment approaches for metastatic ROS1 fusion IMT with previously limited treatment options. Primary care pediatricians and pediatric subspecialists have a crucial role in the early consultation of a pediatric oncology center experienced in molecular diagnostics to facilitate a comprehensive evaluation for children with inflammatory tumors.<\/jats:p>","DOI":"10.1542\/peds.2021-050990","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:17:19Z","timestamp":1637713039000},"source":"Crossref","is-referenced-by-count":9,"title":["Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy"],"prefix":"10.1542","volume":"148","author":[{"given":"Franziska","family":"Wachter","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center and Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyaa","family":"Al-Ibraheemi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Boston Children\u2019s Hospital and Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Trissal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center and Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Hollowell","sequence":"additional","affiliation":[{"name":"Department of Pathology, Boston Children\u2019s Hospital and Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"DuBois","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center and Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie B.","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center and Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna J.","family":"Church","sequence":"additional","affiliation":[{"name":"Department of Pathology, Boston Children\u2019s Hospital and Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Janeway","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center and Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"issue":"12","key":"2021121010403639700_B1","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/00000478-199112000-00005","article-title":"Inflammatory fibrosarcoma of the mesentery and retroperitoneum. A tumor closely simulating inflammatory pseudotumor","volume":"15","author":"Meis","year":"1991","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2021121010403639700_B2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.soc.2016.05.001","article-title":"Refinements in sarcoma classification in the current 2013 World Health Organization classification of tumours of soft tissue and bone","volume":"25","author":"Jo","year":"2016","journal-title":"Surg Oncol Clin N Am"},{"issue":"8","key":"2021121010403639700_B3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/2159-8290.CD-14-0377","article-title":"Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions","volume":"4","author":"Lovly","year":"2014","journal-title":"Cancer Discov"},{"issue":"4","key":"2021121010403639700_B4","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41379-019-0406-6","article-title":"Infantile inflammatory myofibroblastic tumors: clinicopathological and molecular characterization of 12 cases","volume":"33","author":"Lopez-Nunez","year":"2020","journal-title":"Mod Pathol"},{"issue":"5","key":"2021121010403639700_B5","doi-asserted-by":"crossref","first-page":"e28220","DOI":"10.1002\/pbc.28220","article-title":"Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors","volume":"67","author":"Preobrazhenskaya","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2021121010403639700_B6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/his.12910","article-title":"ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours","volume":"69","author":"Yamamoto","year":"2016","journal-title":"Histopathology"},{"issue":"18","key":"2021121010403639700_B7","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","article-title":"Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor","volume":"363","author":"Butrynski","year":"2010","journal-title":"N Engl J Med"},{"key":"2021121010403639700_B8","doi-asserted-by":"crossref","first-page":"10335","DOI":"10.2147\/OTT.S270481","article-title":"Efficacy and resistance of ALK inhibitors in two inflammatory myofibroblastic tumor patients with ALK fusions assessed by whole exome and RNA sequencing","volume":"13","author":"Zhang","year":"2020","journal-title":"OncoTargets Ther"},{"issue":"1","key":"2021121010403639700_B9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13000-020-01031-w","article-title":"Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors","volume":"15","author":"Kang","year":"2020","journal-title":"Diagn Pathol"},{"issue":"28","key":"2021121010403639700_B10","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children\u2019s Oncology Group study","volume":"35","author":"Moss\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021121010403639700_B11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.lungcan.2018.12.016","article-title":"Case report: crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor","volume":"128","author":"Mai","year":"2019","journal-title":"Lung Cancer"},{"key":"2021121010403639700_B12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21037\/pcm-2020-potb-02","article-title":"Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?","volume":"3","author":"Sehgal","year":"2020","journal-title":"Precis Cancer Med"},{"key":"2021121010403639700_B13","doi-asserted-by":"crossref","first-page":"S779","DOI":"10.21037\/tcr.2018.08.11","article-title":"Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors","volume":"7","author":"Sehgal","year":"2018","journal-title":"Transl Cancer Res"},{"issue":"7","key":"2021121010403639700_B14","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann Oncol"},{"issue":"21","key":"2021121010403639700_B15","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2021121010403639700_B16","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jtho.2017.08.002","article-title":"Recent advances in targeting ROS1 in lung cancer","volume":"12","author":"Lin","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"8","key":"2021121010403639700_B17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2021121010403639700_B18","doi-asserted-by":"crossref","first-page":"104015","DOI":"10.1016\/j.lpm.2020.104015","article-title":"Pancreatic and biliary tract involvement in IgG4-related disease","volume":"49","author":"Rebours","year":"2020","journal-title":"Presse Med"},{"key":"2021121010403639700_B19","doi-asserted-by":"crossref","article-title":"Phase 1\/2 TRIDENT-1 study of repotrectinib in patients with ROS1+ or NTRK+ advanced solid tumors","author":"Cho","DOI":"10.1016\/j.jtho.2021.01.251"},{"issue":"3","key":"2021121010403639700_B20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/PAS.0000000000001167","article-title":"Morphologic overlap between inflammatory myofibroblastic tumor and IgG4-related disease: lessons from next-generation sequencing","volume":"43","author":"Taylor","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"2021121010403639700_B21","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jtho.2019.07.005","article-title":"Assessment of a new ROS1 immunohistochemistry clone (SP384) for the identification of ROS1 rearrangements in patients with non-small cell lung carcinoma: the ROSING Study","volume":"14","author":"Conde","year":"2019","journal-title":"J Thorac Oncol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2021-050990\/1210783\/peds_2021050990.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2021-050990\/1210783\/peds_2021050990.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T23:27:26Z","timestamp":1639178846000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/148\/6\/e2021050990\/183425\/Molecular-Characterization-of-Inflammatory-Tumors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,12,1]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2021-050990","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]},"article-number":"e2021050990"}}